pDONR223-IRAK4 Citations (3)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-IRAK4

Articles
Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use. Sun J, Li N, Oh KS, Dutta B, Vayttaden SJ, Lin B, Ebert TS, De Nardo D, Davis J, Bagirzadeh R, Lounsbury NW, Pasare C, Latz E, Hornung V, Fraser ID. Sci Signal. 2016 Jan 5;9(409):ra3. doi: 10.1126/scisignal.aab2191. PubMed
Toll-like receptor mediated inflammation requires FASN-dependent MYD88 palmitoylation. Kim YC, Lee SE, Kim SK, Jang HD, Hwang I, Jin S, Hong EB, Jang KS, Kim HS. Nat Chem Biol. 2019 Sep;15(9):907-916. doi: 10.1038/s41589-019-0344-0. Epub 2019 Aug 19. PubMed
IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity. Freihat LA, Wheeler JI, Wong A, Turek I, Manallack DT, Irving HR. Sci Rep. 2019 Oct 29;9(1):15468. doi: 10.1038/s41598-019-51913-3. PubMed

If you have published an article using this material, please email us at to have your article added to this page.